- Company
- General hospitals to prescribe obesity drug Qsymia
- by Eo, Yun-Ho Apr 23, 2020 06:27am
- Gaining popularity in the obesity treatment market, Qsymia has entered its prescription code in Korean general hospitals. According to pharmaceutical industry, Qsymia (phentermine hydrochloride plus topiramate), co-marketed by Alvogen Korea and Chong Kun Dang, has been recently passed by Drug Committees at the Big Fives including Severan
- Policy
- Chong Kun Dang's own brand botulinum sales countdown
- by Lee, Tak-Sun Apr 23, 2020 06:27am
- Chong Kun Dang's anti-wrinkle agent botulinum toxin will be released to the market soon after receiving national lot release. In the meantime, Chong Kun Dang has been selling Hugel's brand 'Botulax', but it ended the contract last year and prepared to sell its own brand. According to the industry on the 22nd, Chong Kun Dang secured the
- Policy
- Atnahs is insisting on infringement against generics
- by Lee, Tak-Sun Apr 23, 2020 06:26am
- Generic for Bonviva , an osteoporosis treatment drug launched in 2012, was lately caught up in a patent dispute. This is because the changed patent holder is insisting on infringement of indications and dosage patents against generics. According to the industry on the 21st, Atnahs, UK, which took over the patent right of Bonviva from Ro
- Company
- Global companies made KRW 21M per employee last year
- by An, Kyung-Jin Apr 23, 2020 06:26am
- Korea Otsuka Pharmaceutical has generated the highest operating profit per employee last year among Korean branches of multinational pharmaceutical companies. Each employee at the multinational company has made 108 million won worth of operating profit. On Apr. 21, an analysis on 30 multinational pharmaceutical companies in Korea surveyed
- Policy
- Samsung developed mobile blood pressure measurement app
- by Lee, Tak-Sun Apr 23, 2020 06:26am
- The MFDS (Chief Lee Eui-kyung) announced on the 20th that it approved the world's first software as a medical device (SaMD) that measures blood pressure using a 'mobile app'. This medical device is a 'blood pressure app' developed by 'Samsung Electronics Co., Ltd.'. It measures blood pressure easily by using a smart watch (mobile platform) on
- Policy
- MSD, commercialize adult male oral HPV prevention vaccine
- by Lee, Tak-Sun Apr 22, 2020 06:04am
- MSD conducts vaccine clinical trials to prevent oral HPV (human papillomavirus) infection in adult men. MSD has already introduced vaccines to prevent human papillomavirus through 'Gardasil · Gardasil9', but there are no indications for oral HPV prevention in adult men. The MFDS approved IND for phase III of an HPV vaccine (V503) submitte
- Company
- COVID-19 hinders Italian API distribution causing stock-out
- by Jung, Hye-Jin Apr 22, 2020 06:03am
- Due to temporary suspension of active pharmaceutical ingredient (API) distribution amid COVID-19 pandemic, many drugs have been reportedly sold out. The industry experts see that the restricted international logistics of human and material resources during the pandemic has affected a number of drugs to be stocked out for a long and shor
- Policy
- Controversy over Rutatera's exclusion from disaster expenses
- by Lee, Jeong-Hwan Apr 22, 2020 06:02am
- It has been pointed out that the NHIS is causing economic damage to patients by not applying disaster medical expenses to anticancer drugs for the treatment of rare tumors, which has greatly increased the cost of medication due to the COVID-19 pandemic. The NHIS announced that it was unable to apply disaster medical expenses for the reason
- Company
- GSK Korea pays the highest average salary at KRW 136M
- by An, Kyung-Jin Apr 22, 2020 06:02am
- Among all Korean affiliates of multinational pharmaceutical companies, employees at GlaxoSmithKline (GSK) Korea have received the highest average salary of 136 million won. Employees working at Sanofi Pasteur, GSK Consumer Healthcare Korea, Galderma Korea, Allergan Korea, Boehringer Ingelheim Korea and AbbVie Korea have received average salary o
- Opinion
- [FOCUS]We expect the MFDS to act wisely on impurity measures
- by Chon, Seung-Hyun Apr 22, 2020 06:02am
- At the end of September last year, when the MFDS decided to stop selling all products of the anti-ulcer drug “Ranitidine,” the pharmaceutical industry reacted strongly. The MFDS decided to withdraw because Ranitidine has unstable properties and is always exposed to the risk of carcinogenic substance 'N-nitrosodimethylamine (NDMA)'. The p
